CN102861063B - Houttuynoid C在制备治疗或预防肾纤维化的药物中的应用 - Google Patents
Houttuynoid C在制备治疗或预防肾纤维化的药物中的应用 Download PDFInfo
- Publication number
- CN102861063B CN102861063B CN201210418327.1A CN201210418327A CN102861063B CN 102861063 B CN102861063 B CN 102861063B CN 201210418327 A CN201210418327 A CN 201210418327A CN 102861063 B CN102861063 B CN 102861063B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- renal fibrosis
- medicine
- treating
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FCUIRBQXJWMGLZ-YLUJEXTNSA-N 2-(3-decanoyl-7-hydroxy-1-benzofuran-4-yl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C=12C(C(=O)CCCCCCCCC)=COC2=C(O)C=CC=1C=1OC2=CC(O)=CC(O)=C2C(=O)C=1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O FCUIRBQXJWMGLZ-YLUJEXTNSA-N 0.000 title claims abstract description 56
- 201000002793 renal fibrosis Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 102000016359 Fibronectins Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 7
- 230000004761 fibrosis Effects 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 5
- 229960002591 hydroxyproline Drugs 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229930190556 houttuynoid Natural products 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 description 2
- 208000007599 Hyperkalemic periodic paralysis Diseases 0.000 description 2
- 102100027195 Sodium channel protein type 4 subunit alpha Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002665 bowman capsule Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210418327.1A CN102861063B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid C在制备治疗或预防肾纤维化的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210418327.1A CN102861063B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid C在制备治疗或预防肾纤维化的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102861063A CN102861063A (zh) | 2013-01-09 |
CN102861063B true CN102861063B (zh) | 2014-04-16 |
Family
ID=47440381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210418327.1A Active CN102861063B (zh) | 2012-10-27 | 2012-10-27 | Houttuynoid C在制备治疗或预防肾纤维化的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102861063B (zh) |
-
2012
- 2012-10-27 CN CN201210418327.1A patent/CN102861063B/zh active Active
Non-Patent Citations (6)
Title |
---|
Houttuynoids A-E, anti-herpes simplex virus active flavonoids with novel skeletons from houttuynia cordata;Shao-Dan Chen et al;《Organic Letters》;20120313;第14卷(第7期);第1773页 * |
Shao-DanChenetal.HouttuynoidsA-E anti-herpes simplex virus active flavonoids with novel skeletons from houttuynia cordata.《Organic Letters》.2012 |
排毒合剂对慢性肾衰竭纤维指标和肾功能影响的临床研究;高智 等;《新中医》;20071031;第39卷(第10期);第91页 * |
李爽 等.鱼腥草的有效成分、药理作用及临床应用的研究进展.《沈阳药科大学学报》.1997,第14卷(第2期),第144-146页. |
高智 等.排毒合剂对慢性肾衰竭纤维指标和肾功能影响的临床研究.《新中医》.2007,第39卷(第10期),第91页. |
鱼腥草的有效成分、药理作用及临床应用的研究进展;李爽 等;《沈阳药科大学学报》;19970430;第14卷(第2期);第144-146页 * |
Also Published As
Publication number | Publication date |
---|---|
CN102861063A (zh) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105287546A (zh) | Virosaines B在制备治疗和预防肾纤维化药物中的应用 | |
CN102861063B (zh) | Houttuynoid C在制备治疗或预防肾纤维化的药物中的应用 | |
CN102861072B (zh) | Houttuynoid A在制备治疗或预防肾纤维化的药物中的应用 | |
CN102872130B (zh) | Houttuynoid D在治疗或预防肾纤维化的药物中的应用 | |
CN103585149B (zh) | Nitrosporeusines A在治疗和预防肾纤维化药物中的应用 | |
CN102861085B (zh) | Houttuynoid E在制备治疗或预防肾纤维化的药物中的应用 | |
CN107854461A (zh) | Apigenin在制备治疗和预防肾纤维化药物中的应用 | |
CN106265691A (zh) | Friedolanostanes在制备治疗和预防肾纤维化药物中的应用 | |
CN105125568A (zh) | 一种治疗和预防肾纤维化药物及其应用 | |
CN103599095B (zh) | Hippolachnin A在治疗和预防肾纤维化药物中的应用 | |
CN103356659B (zh) | Chukrasone A在制备治疗或预防肾纤维化的药物中的应用 | |
CN103127089A (zh) | Eryngiolide A在治疗或预防肾纤维化的药物中的应用 | |
CN103251603A (zh) | Myriberine A在制备治疗和预防肾纤维化药物中的应用 | |
CN102872042B (zh) | Gypensapogenin B在制备治疗或预防肾纤维化的药物中的应用 | |
CN105395541A (zh) | Perovskone B在制备治疗和预防肾纤维化药物中的应用 | |
CN103520181B (zh) | Phyllanthoid A在制备治疗和预防肾纤维化药物中的应用 | |
CN104188978A (zh) | 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备治疗或预防肾纤维化药物中的应用 | |
CN103585153B (zh) | Caesanines D在治疗和预防肾纤维化药物中的应用 | |
CN103462992B (zh) | Aphanamgrandiol A在制备治疗和预防肾纤维化药物中的应用 | |
CN103463005B (zh) | Racemosins A在制备治疗和预防肾纤维化药物中的应用 | |
CN102872083A (zh) | Houttuynoid B在治疗或预防肾纤维化的药物中的应用 | |
CN103120677A (zh) | Aphanamixoid A在治疗或预防肾纤维化的药物中的应用 | |
CN103381159A (zh) | Chukrasone B在治疗或预防肾纤维化的药物中的应用 | |
CN103356569A (zh) | Sarcaboside B在治疗或预防肾纤维化的药物中的应用 | |
CN103356588A (zh) | Sarcaboside A在制备治疗或预防肾纤维化的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141126 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141126 Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |